Arrowhead Pharmaceuticals earnings missed by $3.56, revenue topped estimates
Arrowhead Pharmaceuticals (ARWR) reported Q4 EPS of -$5.11, missing estimates by $3.56, while revenue of $450.82M exceeded expectations. The stock is down 45.58% over 3 months but up 14.61% over 12 months. Analysts revised EPS estimates mostly downward. InvestingPro rates the company's financial health as 'fair performance.'
How this was made
The 30-second read
Why it matters
The earnings miss highlights execution risk and may trigger re‑rating by analysts.
Market read
The surprise earnings shortfall is a primary catalyst for ARWR and may influence peer biotech stocks.
What to watch
Potential pipeline milestones or upcoming FDA decisions could offset short‑term pain.
Background
Arrowhead Pharmaceuticals is a clinical‑stage biotech focused on RNA‑targeted therapies.
Ticker impact
Arrowhead Pharmaceuticals reported Q4 EPS of -$5.11, missing estimates by $3.56 and revenue of $450.8M versus $59.2M expected.
downward pressure as investors price in the large earnings shortfall
The miss is material and the first report of the numbers; market typically reacts negatively to such a gap.
Market effects
Biotech sector may see broader risk-off sentiment after a high‑profile miss.
US biotech stocks could face short‑term weakness.
Limited to investors tracking small‑cap biotech earnings.
Counterpoint
Some investors may view the miss as a buying opportunity if the stock is oversold.
Key entities
- CompanyArrowhead Pharmaceuticals
NASDAQ‑listed biotech company.
